PRCT:NSD-Procept Biorobotics Corp (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 84.99

Change

0.00 (0.00)%

Market Cap

USD 4.32B

Volume

1.15M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-22 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
DXCM DexCom Inc

N/A

USD 28.22B
PODD Insulet Corporation

N/A

USD 16.59B
BRKR Bruker Corporation

N/A

USD 10.23B
MASI Masimo Corporation

N/A

USD 6.49B
TMDX TransMedics Group Inc

N/A

USD 5.04B
AXNX Axonics Modulation Technologie..

N/A

USD 3.53B
QDEL Quidel Corporation

N/A

USD 3.05B
TNDM Tandem Diabetes Care Inc

N/A

USD 2.92B
LIVN LivaNova PLC

N/A

USD 2.76B
UFPT UFP Technologies Inc

N/A

USD 2.72B

ETFs Containing PRCT

XHE SPDR® S&P Health Care Eq.. 2.22 % 0.35 %

N/A

USD 0.23B
W311:XETRA HAN-GINS Indxx Healthcare.. 1.22 % 0.00 %

N/A

USD 0.02B
W311:F HAN-GINS Indxx Healthcare.. 1.22 % 0.00 %

N/A

USD 0.02B
WELL:PA HAN-GINS Indxx Healthcare.. 1.22 % 0.00 %

N/A

N/A
FYC First Trust Small Cap Gro.. 0.76 % 0.70 %

N/A

USD 0.34B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 102.79% 92% A 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 102.79% 92% A 95% A
Trailing 12 Months  
Capital Gain 163.62% 94% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 163.62% 94% A 96% N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 20.57% 72% C 78% C+
Dividend Return 20.57% 72% C 77% C+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 42.76% 68% D+ 42% F
Risk Adjusted Return 48.10% 93% A 77% C+
Market Capitalization 4.32B 95% A 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector